What conditions is semaglutide approved to treat?

Semaglutide is an FDA-approved prescription medication, and its approvals are not blanket permission to use the molecule however a person wants. They attach to three specific purposes, each gated by its own eligibility criteria: type 2 diabetes in adults, chronic weight management for people who clear set body mass index thresholds, and cardiovascular risk reduction in adults with established cardiovascular disease. The same active ingredient carries different approved uses depending on which brand-name product and dose a clinician prescribes, which is why the approved indication tracks the formulation rather than semaglutide as an abstract substance.

• Type 2 diabetes: Approved in adults alongside diet and exercise to improve glycemic control.
• Chronic weight management: Approved at a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity.
• Cardiovascular risk reduction: Approved to lower major adverse cardiac events in adults with established cardiovascular disease.

Which regulatory body grants semaglutide its approvals and what does an approved indication actually mean?

An approved indication is a regulator's formal statement that a drug may be marketed and prescribed for a defined condition in a defined patient population, and it is the product of a structured scientific review rather than a manufacturer's claim. In the United States that authority rests with the Food and Drug Administration, which weighs the submitted clinical trial data on efficacy and safety and decides whether the benefits outweigh the risks for that exact use. Each indication is evaluated on its own evidence, which is why a single molecule accumulates approvals one at a time as trials are completed.

For which form of diabetes is semaglutide approved and what role does it play in blood sugar management?

Semaglutide is approved for type 2 diabetes mellitus in adults, and the restriction to type 2 reflects how the drug works rather than an arbitrary regulatory line. As a glucagon-like peptide-1 receptor agonist it prompts the pancreas to release insulin only when blood glucose is elevated, suppresses glucagon, and slows gastric emptying so glucose enters the bloodstream more gradually. Type 1 diabetes is characterized by near-total destruction of the insulin-producing beta cells, leaving the drug nothing to stimulate, which is why the approval does not extend to it.

• Approved population: Adults with type 2 diabetes, typically added after or alongside metformin and lifestyle change.
• Mechanism fit: Type 2 retains an impaired but residual insulin capacity for the drug to act on.
• Hypoglycemia profile: Glucose-dependent insulin release gives a low intrinsic hypoglycemia risk when used alone.
• Reported outcome: Clinical trials report meaningful HbA1c reductions, the marker of average blood glucose over roughly three months.

Under what circumstances is semaglutide approved for chronic weight management?

The weight management approval is not open-ended; it is bounded by explicit body mass index criteria, and the word chronic in the indication is deliberate. It signals long-term management of a relapsing condition, distinct from cosmetic or short-term slimming, and the label frames the drug as an adjunct to a reduced-calorie diet and increased physical activity rather than a standalone fix. That framing reflects the trial designs, in which semaglutide was always tested on top of lifestyle change.

What cardiovascular risk reduction indication has semaglutide received and which patients qualify?

The cardiovascular risk reduction indication authorizes semaglutide to lower the likelihood of major adverse cardiovascular events - cardiovascular death, nonfatal heart attack, and nonfatal stroke - in adults who already have established cardiovascular disease. This use does not stand alone: depending on the specific authorization, the patient must also have type 2 diabetes or be living with overweight or obesity, so the cardiovascular indication layers onto one of the other approved populations. The basis is large cardiovascular outcome trials that followed thousands of high-risk patients over several years and reported a statistically significant reduction in the composite event rate compared with placebo.

What body mass index and comorbidity thresholds define eligibility for the weight management indication?

Eligibility for the weight management indication is defined numerically through body mass index, a figure derived by dividing weight in kilograms by the square of height in meters. A BMI of 25 to just under 30 is classified as overweight and 30 or above as obese, and the approved thresholds set two separate entry points off that scale. A comorbidity effectively raises the urgency at a lower weight, because the medical case for pharmacological intervention strengthens when excess weight is already producing or worsening disease.

1. BMI 30 or greater: Qualifies an adult on its own, no additional condition required.
2. BMI 27 to just under 30: Qualifies only when paired with at least one recognized comorbidity, including hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.
3. Adolescents: Thresholds are referenced against age- and sex-specific growth percentiles rather than fixed numbers, since BMI norms shift during development.
4. Regional confirmation: The exact comorbidity lists and wording differ modestly between regulators, so the qualifying criteria are confirmed against local prescribing information.

How do the approved indications differ across the brand names that contain semaglutide?

Semaglutide reaches patients under several brand names, and the differences between them are about indication, dose, and route rather than the molecule itself. Each indication was approved on its own trial program at its own dose, so separating the brands keeps the dosing, labeling, and patient guidance distinct. That separation also means the brands are not freely interchangeable, since substituting one for another changes both the dose and the formally approved use.

What does off-label use of semaglutide mean and where does it fall outside the approved indications?

Off-label use describes prescribing a drug for a condition, population, or dose the regulator has not formally reviewed, even though the drug itself is legally marketed. For semaglutide this commonly means using it in a person whose body mass index sits below the qualifying thresholds for cosmetic weight loss, or in someone with prediabetes rather than diagnosed type 2 diabetes. The prescription is not necessarily improper, since clinicians exercise judgment in many jurisdictions, but the formal benefit-risk review that backs an approved indication is absent, so the evidence base and the accountability shift more heavily onto the prescriber.

Which populations are excluded from or contraindicated for semaglutide despite the approved indications?

Even within an approved indication, certain patients are excluded because the documented risk outweighs the benefit. The most prominent contraindication is a personal or family history of medullary thyroid carcinoma or the genetic syndrome Multiple Endocrine Neoplasia type 2, a restriction that stems from rodent studies in which GLP-1 receptor agonists were associated with thyroid C-cell tumors and that carries a boxed warning even though the human relevance remains uncertain. Several other groups are excluded or flagged for caution based on the safety record, not on a gap in the approval.

• Medullary thyroid carcinoma history or MEN 2: Boxed-warning contraindication based on rodent thyroid C-cell tumor findings.
• Pregnancy and breastfeeding: Excluded, with animal data raising fetal safety concerns; generally discontinued before a planned pregnancy.
• History of pancreatitis: Caution warranted, since GLP-1 agonists have been linked to pancreatic inflammation.
• Severe gastrointestinal disease: Conditions such as gastroparesis may be poorly suited because the drug further slows gastric emptying.